CSBR director exercises 94,405 options at $2.1; holds 1,056,539
Rhea-AI Filing Summary
Champions Oncology (CSBR) director Joel Ackerman reported an insider transaction on Form 4. On 10/30/2025, he exercised stock options for 94,405 shares at $2.1 per share (transaction code M), acquiring the same number of common shares.
After the transaction, he reported 1,056,539 shares beneficially owned directly and 0 derivative securities remaining. The exercised option covered 94,405 underlying shares with a $2.1 exercise price.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 94,405 shares
Net Buy
2 txns
Insider
ACKERMAN JOEL
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to purchase Common Stock | 94,405 | $2.10 | $198K |
| Exercise | Common Stock | 94,405 | $2.10 | $198K |
Holdings After Transaction:
Option to purchase Common Stock — 0 shares (Direct);
Common Stock — 1,056,539 shares (Direct)
Footnotes (1)
- F1. 70,804 options were immediately exercisable on grant date of July 19, 2016, with the remaining options vesting and available to exercise on October 31, 2016.
FAQ
What insider transaction did CSBR report?
A director exercised options for 94,405 shares at $2.1 per share, acquiring the same number of common shares on 10/30/2025.
What was the exercise price and size of the option for CSBR?
The option covered 94,405 underlying shares with a $2.1 exercise price.
What was the Form 4 transaction code for CSBR?
The filing lists transaction code M, indicating an option exercise.
Does the CSBR insider hold any derivative securities after the exercise?
No. The filing shows 0 derivative securities beneficially owned after the reported transaction.
What is the insider’s relationship to CSBR?
The reporting person is a Director of Champions Oncology, Inc.
AI-generated analysis. How Rhea-AI works. Not financial advice.